跳至主要内容
临床试验/CTRI/2025/01/079458
CTRI/2025/01/079458尚未招募4 期

Comparison of injection Iron Isomaltoside with injection Iron Sucrose for treatment of iron deficiency anaemia in pregnancy - A randomized controlled trial

Rohilkhand Medical College and Hospital, Bareilly1 个研究点 分布在 1 个国家目标入组 168 人开始时间: 2025年2月14日最近更新:

试验速览

阶段
4 期
状态
尚未招募
入组人数
168
试验地点
1
主要终点
To determine efficacy of injection iron isomaltoside and injection iron sucrose.

研究概览

简要总结

Anemia is a prevalent health issue in developing countries, including India, and is of particular concern during pregnancy due to its high occurrence and significant impact on maternal and fetal health.

According to the Centers for Disease Control and Prevention (1998), anemia in pregnant women is defined as hemoglobin levels below 11 g/dL in the first and third trimesters and below 10.5 g/dL in the second trimester, using the 5th percentile as the cutoff for iron-supplemented pregnancies.

In India, anemia is predominantly associated with iron deficiency. The National Family Health Survey (NFHS-5) reports that 52.2% of pregnant women aged 15-49 are anemic. Contributing factors include poor nutrition, increased demand from the fetoplacental unit, intestinal hookworm infection, malabsorption due to conditions like gastritis, celiac disease, and inflammatory bowel disease (IBD).

Iron deficiency anemia (IDA) can lead to a range of complications, from mild symptoms like fatigue and shortness of breath to severe, life-threatening outcomes. Adverse perinatal outcomes may include preeclampsia, infections, preterm labor, cardiac failure, and pregnancy loss. During labor, risks include shock, postpartum hemorrhage (PPH), uterine inertia, and cardiac failure. Postpartum complications may include puerperal sepsis, poor lactation, pulmonary embolism, subinvolution, and venous thrombosis. For the infant, intrauterine death (IUD) and low birth weight are potential consequences.

Recognizing IDA in pregnancy as a critical health issue, the scientific community has developed various iron formulations to address this problem, administered via oral or parenteral routes.

Despite the growing use of iron isomaltoside, there is a lack of research specifically focused on its efficacy and safety in the Indian obstetric population, where IDA is a major contributor to maternal morbidity and mortality. This study aims to compare iron isomaltoside with iron sucrose, evaluating their relative effectiveness and safety profiles.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
Female

入选标准

  • Pregnant women at gestation less than 36 weeks with haemoglobin between 7-10 g/dl and MCV less than 80 fl.

排除标准

  • Pregnant women at gestation more than or equal to 36 weeks with anaemia due to causes other than iron deficiency.
  • History of intolerance to parenteral iron.
  • History of multiple allergies.

结局指标

主要结局

To determine efficacy of injection iron isomaltoside and injection iron sucrose.

时间窗: Outcome will be assessed at baseline, which is before intervention, and after 4 weeks of infusion.

To determine adverse effects of injection iron isomaltoside.

时间窗: Outcome will be assessed at baseline, which is before intervention, and after 4 weeks of infusion.

To compare injection iron isomaltoside and injection iron sucrose.

时间窗: Outcome will be assessed at baseline, which is before intervention, and after 4 weeks of infusion.

次要结局

  • Changes in haemoglobin and MCV.(Follow up after 4 weeks.)

研究者

申办方类型
Private medical college
责任方
Principal Investigator
主要研究者

Dr Sanchita Kochhar

Rohilkhand Medical College and Hospital

研究点 (1)

Loading locations...

相似试验